Phase I-II Trial of Decitabine in NSCLC

• 15 pt’s, stage IV NSCLC

• 200-660 mg/m2 IV over 8 h q 5-6 wks

• MTD = 660 mg/m2; DLT = hematologic

• No objective responses; 4 SD > 6 mos (9, 15, 16, 81 mos)

• Cmaxss at MTD = 0.41-16 ug/mL (2-70 nM)

Momparler RL et al., 1997 Anti-Cancer Drugs; Momparler RL & Ayuob, J, 2001 Lung Cancer

Previous slide

Next slide

Back to first slide

View graphic version